N-(1,3,4-thiadiazol-2-yl)benzene sulfonamide | 26907-49-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1,3,4-thiadiazol-2-yl)benzene sulfonamide
• 英文别名: N-[1,3,4]thiadiazol-2-yl-benzenesulfonamide；N-[1,3,4]Thiadiazol-2-yl-benzolsulfonamid；N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide
• CAS: 26907-49-3
• 化学式: C₈H₇N₃O₂S₂
• mdl: MFCD00727974
• 分子量: 241.294
• InChiKey: CQVBWAMMROBBPU-UHFFFAOYSA-N

物化性质

• 沸点：
  418.4±28.0 °C(Predicted)
• 密度：
  1.561±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(1,3,4-thiadiazol-2-yl)benzene sulfonamide 在 sodium acetate 、 溶剂黄146 、 溴 作用下， 反应 1.08h， 以190 mg的产率得到N-(5-bromo-1,3,4-thiadiazol-2-yl)benzene sulfonamide
  参考文献：
  名称：

  NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

  摘要：

  由式[1]表示的化合物（在该式中，Z表示N、CH或类似物；X表示NH或类似物；R表示杂环烷基或类似物；R2、R3和R4中的每一个表示氢原子、卤原子、烷氧基或类似物；R5表示杂环烷基或类似物）或其盐。

  公开号：

  US20150322063A1
• 作为产物：
  描述：

  2-氨基-1,3,4-噻二唑 、 苯磺酰氯 在 吡啶 、 盐酸 作用下， 以 吡啶 为溶剂， 反应 1.08h， 以240 mg的产率得到N-(1,3,4-thiadiazol-2-yl)benzene sulfonamide
  参考文献：
  名称：

  NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

  摘要：

  由式[1]表示的化合物（在该式中，Z表示N、CH或类似物；X表示NH或类似物；R表示杂环烷基或类似物；R2、R3和R4中的每一个表示氢原子、卤原子、烷氧基或类似物；R5表示杂环烷基或类似物）或其盐。

  公开号：

  US20150322063A1

文献信息

• CHEMICAL COMPOUNDS
  申请人：Pfizer Limited

  公开号：US20140315933A1

  公开（公告）日：2014-10-23

  The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or pharmaceutically acceptable salts thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes and to methods of treatment; wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description.

  本发明涉及新的磺胺类URAT-1抑制剂化合物，化学式为(I)或其药用可接受的盐：包含它们的组合物，其制备方法，用于这些方法的中间体以及治疗方法；其中R1、R2、R3、R4、R5和R6如描述中所定义。
• [EN] CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZÈNESULFONAMIDES CYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009080223A1

  公开（公告）日：2009-07-02

  The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the Formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  该发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理功能衍生物，显示出PPARδ或PPARδ和PPARγ激动剂活性。所描述的是Formula (I)的化合物，其中基团如所定义，并且它们的生理上可接受的盐及其制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍，以及胰岛素抵抗相关的疾病，以及中枢和外周神经系统的脱髓鞘化和其他神经退行性疾病。
• PHOTOLYTIC ACID-GENERATING POLYMERS AND MONOMERS FOR THEIR CONSTRUCTION
  申请人：BRAINARD Robert L.

  公开号：US20110130538A1

  公开（公告）日：2011-06-02

  Polymers for photoresists and monomers for incorporation into those polymers are disclosed. The polymers comprise a photoacid generator (PAG) component and at least a second component that is photolytically stable and acid-stable. The polymers may also contain a third, acid-labile component. The photoacid generator is based on N-sulfoxyimides and related moieties that contain photolabile oxygen-heteroatom and oxygen-aromatic carbon bonds.

  本发明揭示了用于光刻胶的聚合物和用于纳入这些聚合物的单体。聚合物包括光酸发生器（PAG）组分和至少第二个组分，该组分具有光解稳定性和酸稳定性。聚合物还可以包含第三种酸不稳定的组分。光酸发生器基于N-磺酰氧亚胺和相关的含有光敏氧杂原子和氧芳香碳键的基团。
• N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE
  申请人：KEIL Stefanie

  公开号：US20090054494A1

  公开（公告）日：2009-02-26

  The present invention comprises N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their physiologically acceptable salts and functional derivatives that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, And the isomers thereof wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及N-[1,3,4]-噻二唑-2-基苯磺酰胺、其生理上可接受的盐和功能衍生物，它们表现出过氧化物酶体增殖物激活受体(PPAR) PPARδ和PPARγ激动剂活性。发明中的化合物的结构由下式I定义，以及其异构体，其中各种取代基在此定义，包括其生理上可接受的盐。还公开了制备这些化合物的方法。这些化合物适用于治疗涉及脂肪酸代谢和葡萄糖利用障碍、涉及胰岛素抵抗的疾病，以及中枢和周围神经系统的脱髓鞘和其他神经退行性疾病的治疗。
• BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE
  申请人：SCHOENAFINGER Karl

  公开号：US20080293780A1

  公开（公告）日：2008-11-27

  The present invention comprises bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, their functional derivatives thereof as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及双环芳基磺酸[1,3,4]-噻二唑-2-基酰胺及其功能衍生物，以及其生理可接受的盐和药物组合物，其表现出过氧化物酶体增殖物激活受体（PPAR）PPARδ和PPARγ激动剂活性。本发明化合物的结构由下式I定义，其中各种取代基在此定义，包括其生理可接受的盐。本发明还揭示了化合物的制备方法。该化合物适用于治疗与脂肪酸代谢和葡萄糖利用障碍有关的疾病，涉及胰岛素抵抗以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。